The vaccine, which was supported by $1.8 billion in taxpayer funding, uses a more traditional approach than some other COVID-19 vaccines allowed in the USA.
FDA panel recommends Novavax COVID-19 vaccine be the fourth allowed for use in US
Related Articles
